Characteristics of 20 included trials in the meta-analysis (n = 6433).

Abbreviation: GEM, gemcitabine; CDDP, cisplatin; VP-16, etoposide; DOC, docetaxel; MIC, Mitomycin+IFO+cisplatin; MVAC, methotrexate+vinblastine+doxorubicin+cisplatin; CBP, carboplatin; IFO, ifosfamide; EPI, epirubicin; NVB, vinorelbine; PTX, paclitaxel; FU, fluorouracil; CTX, cyclophosphamide; PEM, pemetrexed; CPT-11, irinotecan; BEV, bevacizumab; SOR, sorafenib; GI, gastrointestinal tract; NSCLC, non-small-cell lung cancer; MBC; metastatic breast cancer; PFS, progression-free survival; TTP, time-to progression; OS, overall survival; NR, not reported;